TREND-HD

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial of Ethyl-EPA (Miraxion™) in Subjects with Mild to Moderate Huntington's Disease

The TREND-HD study is a clinical trial being conducted at more than 40 research centers in North America (US and Canada) for people ages 35 and older who have mild to moderate Huntington's disease (HD). Each research center will enroll approximately 7-8 people with HD.  The study will last one year (12 months).

The main purpose of this study is to determine whether the use of ethyl-EPA, an experimental drug, improves chorea, the involuntary movements associated with Huntington's disease.

Enrollment is closed.